BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 38632563)

  • 1. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
    Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
    Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel SLC3A2-targeting antibody-drug conjugate exerts potent antitumor efficacy in head and neck squamous cell cancer.
    Zheng M; Wang Z; Li M; Yang N; Lu H; Zhang Z; Dong Y; Chen Y; Zhu Z; Tong A; Yang H
    Transl Oncol; 2024 Jul; 45():101981. PubMed ID: 38703658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER3 to overcome EGFR TKI resistance in NSCLC.
    Chen Q; Jia G; Zhang X; Ma W
    Front Immunol; 2023; 14():1332057. PubMed ID: 38239350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
    Yonesaka K
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
    Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
    J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
    Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
    Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
    Yu HA; Baik C; Kim DW; Johnson ML; Hayashi H; Nishio M; Yang JC; Su WC; Gold KA; Koczywas M; Smit EF; Steuer CE; Felip E; Murakami H; Kim SW; Su X; Sato S; Fan PD; Fujimura M; Tanaka Y; Patel P; Sternberg DW; Sellami D; Jänne PA
    Ann Oncol; 2024 May; 35(5):437-447. PubMed ID: 38369013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
    Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
    Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
    Oliveira M; Falato C; Cejalvo JM; Vila MM; Tolosa P; Salvador-Bofill FJ; Cruz J; Arumi M; Luna AM; Guerra JA; Vidal M; Martínez-Sáez O; Paré L; González-Farré B; Sanfeliu E; Ciruelos E; Espinosa-Bravo M; Pernas S; Izarzugaza Y; Esker S; Fan PD; Parul P; Santhanagopal A; Sellami D; Villacampa G; Ferrero-Cafiero JM; Pascual T; Prat A
    Ann Oncol; 2023 Aug; 34(8):670-680. PubMed ID: 37211044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer gene expression analysis of tissue microarray using EdgeSeq oncology biomarker panel and a cross-comparison with HER2 and HER3 immunohistochemical analysis.
    Inaki K; Shibutani T; Maeda N; Eppenberger-Castori S; Nicolet S; Kaneda Y; Koyama K; Qiu Y; Wakita K; Murakami M
    PLoS One; 2022; 17(9):e0274140. PubMed ID: 36137139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
    Fu Z; Li S; Han S; Shi C; Zhang Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
    Lim SM; Kim CG; Lee JB; Cho BC
    Cancer Discov; 2022 Jan; 12(1):16-19. PubMed ID: 35022206
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.